FCGR3A and rheumatoid arthritis: Inclusion of a CD16 blocking antibody inhibited rituximab-induced NK-cell degranulation in HC (Mann–Whitney test; p = 0.003) and RA (Mann–Whitney test; p = 0.03, Fig. 4g), supporting a major role for FcγRIIIa in NK-cell-mediated ADCC ex vivo.